- Trial phase
- Approved
- Time to market
- Already approved and marketed in the US (since 2017) and EU (since 2017).
- Why 3/10
- No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for Refixia/Rebinyn in the next 12 months. The drug is fully approved and commercialized in both the US and EU. It represents a small fraction of Novo Nordisk's overall value, which is overwhelmingly driven by GLP-1 diabetes/obesity products.
Refixia/Rebinyn is a mature, approved product with no upcoming binary catalysts. Watch for quarterly Novo Nordisk rare disease segment revenue trends and any competitive developments from CSL's Hemgenix gene therapy or newer non-factor therapies like Mim8 (denecimig) that could shift the hemophilia B treatment landscape.
Price Chart
Executive Summary
Refixia (nonacog beta pegol, sold as Rebinyn in the US) is an extended half-life recombinant factor IX replacement therapy for hemophilia B, developed and marketed by Novo Nordisk (NYSE: NVO). It was approved by the EMA in June 2017 and by the FDA in May 2017, with a subsequent FDA label expansion for routine prophylaxis in July 2022. The drug is fully commercialized in both major markets and competes in a crowded factor IX replacement market against other extended half-life products (Alprolix, Idelvion) and faces long-term disruption risk from gene therapy (Hemgenix). For Novo Nordisk, a company valued primarily on its GLP-1 franchise (Ozempic, Wegovy), Refixia is a small, mature rare-disease product with no upcoming binary catalysts.
How It Works
Refixia is a replacement therapy for hemophilia B, a genetic bleeding disorder where patients lack a functional blood-clotting protein called factor IX. The drug is a lab-made version of factor IX that has been chemically modified with a PEG molecule (a common pharmaceutical technique) to make it last longer in the body. When injected into a vein, it temporarily restores the missing clotting factor, allowing blood to clot normally. Patients use it either on-demand to stop bleeding episodes or as a weekly preventive (prophylaxis) to reduce the frequency of bleeds.
Trial Status
Refixia/Rebinyn was approved based on the Phase 3 Paradigm clinical program. Long-term follow-up studies (including 5-year pediatric data from Paradigm 5) have been completed, confirming sustained safety and efficacy. The drug is fully commercialized with no active pivotal trials seeking initial approval.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates, regulatory decisions, or pivotal readouts are scheduled for Refixia/Rebinyn in the next 12 months. The drug is a mature, approved product.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report